BIOS Capital Management, LP
Long book
$52.9M
Q1 2026
Positions
6
Top-10 weight
100%
concentration
Last quarter
-17.7%
SPY +14.8%
Turnover
0%
of book per quarter
Strategy in plain words
auto-generated from filingsBIOS Capital Management, LP is a diversified fundamental manager, specialised in healthcare (100% of the long book), running a $52.9M US long book across 6 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The book barely moves quarter to quarter — a patient, low-turnover holder. Current anchor positions: ACTUATE THERAPEUTICS INC, OPUS GENETICS INC, COGNITION THERAPEUTICS INC, REIN THERAPEUTICS INC, LANTERN PHARMA INC.
Over the last 6 quarters its long book ran on average 15.6pp per quarter behind the S&P 500, beating the index in 1 of 6 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q4 2024
-15.9%
Q1 2025
-11.6%
Q2 2025
+21.4%
Q3 2025
-6.2%
Q4 2025
-36.1%
Q1 2026
-17.7%
Sector allocation
Healthcare 100%
Long book by quarter
What does BIOS Capital own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| ACTU ACTUATE THERAPEUTICS INC | Healthcare | 10.0M | $27.5M | 52.1% | Held |
| IRD OPUS GENETICS INC | Healthcare | 3.7M | $16.8M | 31.7% | Held |
| CGTX COGNITION THERAPEUTICS INC | Healthcare | 6.0M | $4.6M | 8.6% | Held |
| RNTX REIN THERAPEUTICS INC | Healthcare | 2.0M | $2.6M | 4.9% | +17.2% |
| LTRN LANTERN PHARMA INC | Healthcare | 864.4K | $1.2M | 2.2% | -14.4% |
| INAB IN8BIO INC | Healthcare | 167.8K | $248K | 0.5% | -33.8% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 13, 2026 | 10 | $52.9M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 13, 2026 | 9 | $82.6M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 12, 2025 | 9 | $88.9M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 12, 2025 | 9 | $72.6M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 14, 2025 | 9 | $79.2M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR/ARESTATEMENT | Feb 18, 2025 | 9 | $94.1M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 10, 2025 | 9 | $95.9M | SEC ↗ |